๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Advanced Neuroendocrine Carcinoma

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Zhengzhou๐Ÿ“ Hangzhou Beijing Tide Pharmaceutical Co., Ltd ยท Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Columbus Tanabe Pharma America, Inc. ยท Tests: MT-4561 A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors NCT05366478Phase 11 site๐Ÿ“ Tianjin Suzhou BlueHorse Therapeutics Co., Ltd. ยท Tests: Autologous tumor infiltrating lymphocytes (TILs) Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Shanghai GV20 Therapeutics ยท Tests: GV20-0251 Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. NCT06440057Phase 1, Phase 21 site๐Ÿ“ Beijing Suzhou Zelgen Biopharmaceuticals Co.,Ltd ยท Tests: ZG006 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites๐Ÿ“ Clovis๐Ÿ“ Los Angeles๐Ÿ“ Newport Beach Bristol-Myers Squibb ยท Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites๐Ÿ“ Aurora๐Ÿ“ Lake Mary๐Ÿ“ Lebanon 7 Hills Pharma, LLC ยท Tests: Alintegimod, Ipilimumab, Nivolumab Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites๐Ÿ“ Manchester๐Ÿ“ Sutton Institute of Cancer Research, United Kingdom ยท Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites๐Ÿ“ Grand Rapids๐Ÿ“ St Louis๐Ÿ“ Pittsburgh AstraZeneca ยท Tests: AZD6750, rilvegostomig Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) NCT07016230Phase 23 sites๐Ÿ“ Bordeaux๐Ÿ“ Nice๐Ÿ“ Villejuif Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Tarlatamab A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer NCT06636435Phase 15 sites๐Ÿ“ Kashiwa๐Ÿ“ Yokohama๐Ÿ“ Niigata Chiome Bioscience Inc. ยท Tests: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4, CBA-1205 Part 5 FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum NCT06393816Phase 231 sites๐Ÿ“ Aix-en-Provence๐Ÿ“ Amiens๐Ÿ“ Angers Centre Leon Berard ยท Tests: Durvalumab with etoposide and Carboplatin/Cisplatin EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ยฑ Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site๐Ÿ“ Beijing Essen Biotech ยท Tests: EBNK-001 + IL-15 + Pembrolizumab A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ New Haven GV20 Therapeutics ยท Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDAยฎ], GV20-0251 and Pembrolizumab [KEYTRUDAยฎ] Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites๐Ÿ“ Iowa City๐Ÿ“ Boston๐Ÿ“ Royal Oak Novartis Pharmaceuticals ยท Tests: 225Ac-ETN029, 111In-ETN029 Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung NCT05058651Phase 2, Phase 3265 sites๐Ÿ“ Anchorage๐Ÿ“ Phoenix๐Ÿ“ Phoenix National Cancer Institute (NCI) ยท Tests: Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors NCT07070232Phase 1, Phase 277 sites๐Ÿ“ Phoenix๐Ÿ“ San Francisco๐Ÿ“ Hartford BioNTech SE ยท Tests: BNT326, Pumitamig, Itraconazole, Paroxetine GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites๐Ÿ“ Goyang-si๐Ÿ“ Seoul๐Ÿ“ Seoul GeneMedicine Co., Ltd. ยท Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites๐Ÿ“ Beijing๐Ÿ“ Changsha๐Ÿ“ Nanchang Hangzhou DAC Biotechnology Co., Ltd. ยท Tests: DXC014 Sapu003 in Advanced mTOR-sensitive Solid Tumors NCT07369505Phase 11 site๐Ÿ“ Adelaide SAPU NANO (US) LLC ยท Tests: Sapu003, Exemestane 25 MG A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors NCT07600476Phase 13 sites๐Ÿ“ Munich๐Ÿ“ Wรผrzburg๐Ÿ“ Mรผnster Kupando GmbH ยท Tests: KUP-101A Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) NCT06816394Phase 21 site๐Ÿ“ Taipei National Taiwan University Hospital ยท Tests: Tarlatamab Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites๐Ÿ“ Scottsdale๐Ÿ“ Bethesda๐Ÿ“ Columbus Novartis Pharmaceuticals ยท Tests: dabrafenib, trametinib MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760Phase 12 sites๐Ÿ“ Tampa๐Ÿ“ Durham Memgen, Inc. ยท Tests: MEM-288 Intratumoral Injection, Nivolumab, Docetaxel A Study of CRD3874-SI in People With Solid Tumors NCT06021626Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: CRD3874 BostonGene and Exigent Genomic INsight Study NCT06272864n/a7 sites๐Ÿ“ Rogers๐Ÿ“ Stockton๐Ÿ“ Fort Wayne BostonGene Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab NCT07751042Phase 1, Phase 24 sites๐Ÿ“ Scottsdale๐Ÿ“ Boston๐Ÿ“ Nashville Strand Therapeutics Inc. ยท Tests: STX-003, KEYTRUDAยฎ Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer NCT06283719Phase 1, Phase 21 site๐Ÿ“ Shanghai Suzhou Zelgen Biopharmaceuticals Co.,Ltd ยท Tests: ZG006
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy